SEC Form 4/A · accession 0001019056-16-001559
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Scott C Stromatt
Officer — Chief Medical Officer and SVP
Period of report
Aug 3, 2016
Accepted (ET)
Sep 27, 2016 · 3:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 2,244 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3 | — | Aug 3, 2016 | A | 54,762 | A | — | — | Common Stock | 54,762 | 54,762 | D |
| Restricted Stock UnitF5,F2,F4 | — | Aug 3, 2016 | A | 78,123 | A | — | — | Common Stock | 78,123 | 234,322 | D |
| Stock Option (right to buy)F6,F7,F8,F9 | — | holding | — | — | — | — | — | Common Stock | 202,880 | 202,880 | D |
Explanation of responses
- F1This report has been amended to reflect the number of shares received in a pro rata distribution by Emergent BioSolutions, Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective on August 1, 2016.
- F2Each RSU represents the right of the reporting person to receive one share of common stock of the Issuer.
- F3This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018.
- F4This report has been amended to reflect that the RSUs will vest on August 1, 2017.
- F5This report has been amended to reflect the 101,437 RSUs that were originally issued by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan.
- F6This report has been amended to include the stock options that were originally granted by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan.
- F749,682 of the Reporting Person's stock options are exercisable at an exercise price of $2.47 per share; 55,586 of the Reporting Person's stock options are exercisable at an exercise price of $2.55 per share; and 97,612 of the Reporting Person's stock options are exercisable at an exercise price $2.97.
- F849,682 of the Reporting Persons stock options vest fully on March 10, 2017; 55,586 of the Reporting Person's stock options vest in two equal installments on March 9, 2017 and March 9, 2018; and 97,612 of the Reporting Person's stock options vest as follows: 32,538 on March 1, 2017; 32,538 on March 1, 2018 and 32,536 on March 1, 2019.
- F949,682 of the Reporting Persons stock options expire on March 10, 2021; 55,586 of the Reporting Person's stock options expire on March 9, 2022; and 97,612 expire on February 28, 2026.